REG - Cambridge Cognition - Change of Joint Broker

Cambridge Cognition HoldingsAnnouncement

09/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260209:nRSI2072Sa&default-theme=true

RNS Number : 2072S  Cambridge Cognition Holdings PLC  09 February 2026

09 February 2026

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Change of Joint Broker

 

Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology
company whose digital cognitive assessments drive scientific discovery,
accelerate drug development and improve patient care, announces the
appointment of Singer Capital Markets as Joint Corporate Broker with immediate
effect following the transfer of Dowgate Capital's corporate broking, advisory
and research team to Singer Capital Markets.

 

For further information, please contact:

 

 Cambridge Cognition Holdings plc                  Tel: 01223 810700

 Rob Baker, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)

 Ronald Openshaw, Chief Financial Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Will Goode / Mark Rogers / Freddy Crossley        (Corporate Finance)

 Rupert Dearden                                    (Corporate Broking)

 Singer Capital Markets (Joint Broker)             Tel: 020 7496 3000

 Amber Higgs / James Serjeant / Daniel Ingram

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a neuroscience technology company whose digital
cognitive assessments drive scientific discovery, accelerate drug development
and improve patient care.

 

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

 

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

 

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPUWAKRNVUURAR



            Copyright 2019 Regulatory News Service, all rights reserved